Skip to main content
Top
Published in:

Open Access 01-12-2024 | Myocardial Infarction | Research

Role of plasma neuropeptide Y in acute myocardial infarction: a case-control study

Authors: Yan-li Zheng, Hui-li Lin, Yue-ting Li, Mei-mei Li, Jing-ru Du, Wan-da Wang, Yao-guo Wang, Yin-lian Cai

Published in: BMC Cardiovascular Disorders | Issue 1/2024

Login to get access

Abstract

Background

As neuropeptide Y is associated with endothelial dysfunction, this study explored the relationship between neuropeptide Y and acute myocardial infarction.

Methods

We included 128 acute myocardial infarction cases and 62 controls. Using the SYNTAX scoring system, the acute myocardial infarction group was sub-grouped into “SYNTAX ≤ 22,” “SYNTAX = 23–32,” and “SYNTAX ≥ 33.” Plasma neuropeptide Y, endothelin, endothelial nitric oxide synthase, and thromboxane A2 levels were measured.

Results

The acute myocardial infarction group had higher plasma neuropeptide Y, endothelin, and thromboxane A2 levels than controls ([58.76 ± 17.63 vs. 37.48 ± 11.36 ng/ml, P = 0.000], [36.16 ± 10.04 vs. 27.80 ± 7.18 pg/ml, P = 0.000], and [27.69 ± 6.91 vs. 24.32 ± 7.28 pg/ml, P = 0.002], respectively). The acute myocardial infarction group also had lower plasma endothelial nitric oxide synthase levels than controls (3.00 ± 0.94 vs. 4.05 ± 1.44 ng/ml, P = 0.000). Additionally, the receiver operating characteristic curve analysis showed that a neuropeptide Y value of 49.94 ng/ml could help diagnose acute myocardial infarction (sensitivity: 70.9%; specificity: 91.9%). The SYNTAX scores, smoking, plasma endothelin, thromboxane A2, and neuropeptide Y levels were positively correlated, whereas plasma endothelial nitric oxide synthase and neuropeptide Y levels were negatively correlated. Lastly, plasma neuropeptide Y levels were different among subgroups (P < 0.05); patients with higher SYNTAX scores had higher neuropeptide Y levels.

Conclusions

The levels of plasma NPY may be accociated with the AMI process.
Appendix
Available only for authorised users
Literature
1.
go back to reference Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 1998;339(19):1349-57. https://doi.org/10.1056/NEJM199811053391902. PMID: 9841303. Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 1998;339(19):1349-57. https://​doi.​org/​10.​1056/​NEJM199811053391​902. PMID: 9841303.
2.
go back to reference Chapman AR, Adamson PD, Shah ASV, Anand A, Strachan FE, Ferry AV, Lee KK, Berry C, Findlay I, Cruikshank A, Reid A, Gray A, Collinson PO, Apple F, McAllister DA, Maguire D, Fox KAA, Vallejos CA, Keerie C, Weir CJ, Newby DE, Mills NL. High-STEACS investigators. High-sensitivity Cardiac Troponin and the Universal Definition of myocardial infarction. Circulation. 2020;141(3):161–71. Epub 2019 Oct 7. PMID: 31587565; PMCID: PMC6970546.CrossRefPubMed Chapman AR, Adamson PD, Shah ASV, Anand A, Strachan FE, Ferry AV, Lee KK, Berry C, Findlay I, Cruikshank A, Reid A, Gray A, Collinson PO, Apple F, McAllister DA, Maguire D, Fox KAA, Vallejos CA, Keerie C, Weir CJ, Newby DE, Mills NL. High-STEACS investigators. High-sensitivity Cardiac Troponin and the Universal Definition of myocardial infarction. Circulation. 2020;141(3):161–71. Epub 2019 Oct 7. PMID: 31587565; PMCID: PMC6970546.CrossRefPubMed
3.
go back to reference Engstrøm T, Kelbæk H, Helqvist S, Høfsten DE, Kløvgaard L, Holmvang L, Jørgensen E, Pedersen F, Saunamäki K, Clemmensen P, De Backer O, Ravkilde J, Tilsted HH, Villadsen AB, Aarøe J, Jensen SE, Raungaard B, Køber L. DANAMI-3—PRIMULTI Investigators. Complete revascularisation versus treatment of the culprit lesion only in patients with ST-segment elevation myocardial infarction and multivessel disease (DANAMI-3—PRIMULTI): an open-label, randomised controlled trial. Lancet. 2015;386(9994):665 – 71. https://doi.org/10.1016/s0140-6736(15)60648-1. PMID: 26347918. Engstrøm T, Kelbæk H, Helqvist S, Høfsten DE, Kløvgaard L, Holmvang L, Jørgensen E, Pedersen F, Saunamäki K, Clemmensen P, De Backer O, Ravkilde J, Tilsted HH, Villadsen AB, Aarøe J, Jensen SE, Raungaard B, Køber L. DANAMI-3—PRIMULTI Investigators. Complete revascularisation versus treatment of the culprit lesion only in patients with ST-segment elevation myocardial infarction and multivessel disease (DANAMI-3—PRIMULTI): an open-label, randomised controlled trial. Lancet. 2015;386(9994):665 – 71. https://​doi.​org/​10.​1016/​s0140-6736(15)60648-1. PMID: 26347918.
4.
go back to reference Thiele H, Akin I, Sandri M, Fuernau G, de Waha S, Meyer-Saraei R, Nordbeck P, Geisler T, Landmesser U, Skurk C, Fach A, Lapp H, Piek JJ, Noc M, Goslar T, Felix SB, Maier LS, Stepinska J, Oldroyd K, Serpytis P, Montalescot G, Barthelemy O, Huber K, Windecker S, Savonitto S, Torremante P, Vrints C, Schneider S, Desch S, Zeymer U. CULPRIT-SHOCK investigators. PCI strategies in patients with Acute myocardial infarction and cardiogenic shock. N Engl J Med. 2017;377(25):2419–32. https://doi.org/10.1056/NEJMoa1710261. Epub 2017 Oct 30. PMID: 29083953.CrossRefPubMed Thiele H, Akin I, Sandri M, Fuernau G, de Waha S, Meyer-Saraei R, Nordbeck P, Geisler T, Landmesser U, Skurk C, Fach A, Lapp H, Piek JJ, Noc M, Goslar T, Felix SB, Maier LS, Stepinska J, Oldroyd K, Serpytis P, Montalescot G, Barthelemy O, Huber K, Windecker S, Savonitto S, Torremante P, Vrints C, Schneider S, Desch S, Zeymer U. CULPRIT-SHOCK investigators. PCI strategies in patients with Acute myocardial infarction and cardiogenic shock. N Engl J Med. 2017;377(25):2419–32. https://​doi.​org/​10.​1056/​NEJMoa1710261. Epub 2017 Oct 30. PMID: 29083953.CrossRefPubMed
5.
go back to reference Persson H, Andréasson K, Kahan T, Eriksson SV, Tidgren B, Hjemdahl P, Hall C, Erhardt L. Neurohormonal activation in heart failure after acute myocardial infarction treated with beta-receptor antagonists. Eur J Heart Fail. 2002;4(1):73–82. https://doi.org/10.1016/s1388-9842(01)00196-9. PMID: 11812667. Persson H, Andréasson K, Kahan T, Eriksson SV, Tidgren B, Hjemdahl P, Hall C, Erhardt L. Neurohormonal activation in heart failure after acute myocardial infarction treated with beta-receptor antagonists. Eur J Heart Fail. 2002;4(1):73–82. https://​doi.​org/​10.​1016/​s1388-9842(01)00196-9. PMID: 11812667.
7.
8.
go back to reference Bahmannia M, Azizzade M, Heydari S, Nasrollahzadeh J, Rabiei S, Naja F, Sheikhi Mobarakeh Z, Hejazi J, Hejazi E. Effects of decaffeinated green coffee extract supplementation on anthropometric indices, blood glucose, leptin, adiponectin and neuropeptide Y (NPY) in breast cancer survivors: a randomized clinical trial. Food Funct. 2022;13(19):10347–10356. https://doi.org/10.1039/d2fo00983h. PMID: 36134465. Bahmannia M, Azizzade M, Heydari S, Nasrollahzadeh J, Rabiei S, Naja F, Sheikhi Mobarakeh Z, Hejazi J, Hejazi E. Effects of decaffeinated green coffee extract supplementation on anthropometric indices, blood glucose, leptin, adiponectin and neuropeptide Y (NPY) in breast cancer survivors: a randomized clinical trial. Food Funct. 2022;13(19):10347–10356. https://​doi.​org/​10.​1039/​d2fo00983h. PMID: 36134465.
10.
go back to reference Tonetti MS, D’Aiuto F, Nibali L, Donald A, Storry C, Parkar M, Suvan J, Hingorani AD, Vallance P, Deanfield J. Treatment of periodontitis and endothelial function. N Engl J Med. 2007;356(9):911 – 20. https://doi.org/10.1056/NEJMoa063186. Erratum in: N Engl J Med. 2018;:null. PMID: 17329698. Tonetti MS, D’Aiuto F, Nibali L, Donald A, Storry C, Parkar M, Suvan J, Hingorani AD, Vallance P, Deanfield J. Treatment of periodontitis and endothelial function. N Engl J Med. 2007;356(9):911 – 20. https://​doi.​org/​10.​1056/​NEJMoa063186. Erratum in: N Engl J Med. 2018;:null. PMID: 17329698.
13.
go back to reference Shahrivari M, Wise E, Resende M, Shuster JJ, Zhang J, Bolli R, Cooke JP, Hare JM, Henry TD, Khan A, Taylor DA, Traverse JH, Yang PC, Pepine CJ, Cogle CR, Cardiovascular Cell Therapy Research Network (CCTRN). Peripheral blood cytokine levels after Acute myocardial infarction: IL-1β- and IL-6-Related impairment of bone marrow function. Circ Res. 2017;120(12):1947–57. Epub 2017 May 10. PMID: 28490433; PMCID: PMC5508725.CrossRefPubMedPubMedCentral Shahrivari M, Wise E, Resende M, Shuster JJ, Zhang J, Bolli R, Cooke JP, Hare JM, Henry TD, Khan A, Taylor DA, Traverse JH, Yang PC, Pepine CJ, Cogle CR, Cardiovascular Cell Therapy Research Network (CCTRN). Peripheral blood cytokine levels after Acute myocardial infarction: IL-1β- and IL-6-Related impairment of bone marrow function. Circ Res. 2017;120(12):1947–57. Epub 2017 May 10. PMID: 28490433; PMCID: PMC5508725.CrossRefPubMedPubMedCentral
14.
go back to reference Holte E, Kleveland O, Ueland T, Kunszt G, Bratlie M, Broch K, Michelsen AE, Bendz B, Amundsen BH, Aakhus S, Damås JK, Gullestad L, Aukrust P, Wiseth R. Effect of interleukin-6 inhibition on coronary microvascular and endothelial function in myocardial infarction. Heart. 2017;103(19):1521–7. https://doi.org/10.1136/heartjnl-2016-310875. Epub 2017 Apr 21. PMID: 28432157.CrossRefPubMed Holte E, Kleveland O, Ueland T, Kunszt G, Bratlie M, Broch K, Michelsen AE, Bendz B, Amundsen BH, Aakhus S, Damås JK, Gullestad L, Aukrust P, Wiseth R. Effect of interleukin-6 inhibition on coronary microvascular and endothelial function in myocardial infarction. Heart. 2017;103(19):1521–7. https://​doi.​org/​10.​1136/​heartjnl-2016-310875. Epub 2017 Apr 21. PMID: 28432157.CrossRefPubMed
17.
go back to reference Herring N, Tapoulal N, Kalla M, Ye X, Borysova L, Lee R, Dall’Armellina E, Stanley C, Ascione R, Lu CJ, Banning AP, Choudhury RP, Neubauer S, Dora K, Kharbanda RK, Channon KM. Oxford Acute myocardial infarction (OxAMI) Study. Neuropeptide-Y causes coronary microvascular constriction and is associated with reduced ejection fraction following ST-elevation myocardial infarction. Eur Heart J. 2019;40(24):1920–9. https://doi.org/10.1093/eurheartj/ehz115. PMID: 30859228; PMCID: PMC6588241.CrossRefPubMedPubMedCentral Herring N, Tapoulal N, Kalla M, Ye X, Borysova L, Lee R, Dall’Armellina E, Stanley C, Ascione R, Lu CJ, Banning AP, Choudhury RP, Neubauer S, Dora K, Kharbanda RK, Channon KM. Oxford Acute myocardial infarction (OxAMI) Study. Neuropeptide-Y causes coronary microvascular constriction and is associated with reduced ejection fraction following ST-elevation myocardial infarction. Eur Heart J. 2019;40(24):1920–9. https://​doi.​org/​10.​1093/​eurheartj/​ehz115. PMID: 30859228; PMCID: PMC6588241.CrossRefPubMedPubMedCentral
21.
go back to reference Safarian H, Alidoosti M, Shafiee A, Salarifar M, Poorhosseini H, Nematipour E. The SYNTAX score can predict major adverse cardiac events following percutaneous coronary intervention. Heart Views. 2014 Oct-Dec;15(4):99–105. PMID: 25774251; PMCID: PMC4348991. Safarian H, Alidoosti M, Shafiee A, Salarifar M, Poorhosseini H, Nematipour E. The SYNTAX score can predict major adverse cardiac events following percutaneous coronary intervention. Heart Views. 2014 Oct-Dec;15(4):99–105. PMID: 25774251; PMCID: PMC4348991.
22.
go back to reference Kalla M, Hao G, Tapoulal N, Tomek J, Liu K, Woodward L; ‘Oxford Acute Myocardial Infarction (OxAMI) Study’; Dall’Armellina, Banning E, Choudhury AP, Neubauer RP, Kharbanda S, Channon RK, Ajijola KM, Shivkumar OA, Paterson K, Herring DJ. N. The cardiac sympathetic co-transmitter neuropeptide Y is pro-arrhythmic following ST-elevation myocardial infarction despite beta-blockade. Eur Heart J. 2020;41(23):2168–2179. https://doi.org/10.1093/eurheartj/ehz852. PMID: 31834357; PMCID: PMC7299634. Kalla M, Hao G, Tapoulal N, Tomek J, Liu K, Woodward L; ‘Oxford Acute Myocardial Infarction (OxAMI) Study’; Dall’Armellina, Banning E, Choudhury AP, Neubauer RP, Kharbanda S, Channon RK, Ajijola KM, Shivkumar OA, Paterson K, Herring DJ. N. The cardiac sympathetic co-transmitter neuropeptide Y is pro-arrhythmic following ST-elevation myocardial infarction despite beta-blockade. Eur Heart J. 2020;41(23):2168–2179. https://​doi.​org/​10.​1093/​eurheartj/​ehz852. PMID: 31834357; PMCID: PMC7299634.
23.
go back to reference Tiller C, Reindl M, Holzknecht M, Lechner I, Troger F, Oberhollenzer F, von der Emde S, Kremser T, Mayr A, Bauer A, Metzler B, Reinstadler SJ. Relation of plasma neuropeptide-Y with myocardial function and infarct severity in acute ST-elevation myocardial infarction. Eur J Intern Med. 2024;126:63–8. Epub 2024 Mar 29. PMID: 38555253.CrossRefPubMed Tiller C, Reindl M, Holzknecht M, Lechner I, Troger F, Oberhollenzer F, von der Emde S, Kremser T, Mayr A, Bauer A, Metzler B, Reinstadler SJ. Relation of plasma neuropeptide-Y with myocardial function and infarct severity in acute ST-elevation myocardial infarction. Eur J Intern Med. 2024;126:63–8. Epub 2024 Mar 29. PMID: 38555253.CrossRefPubMed
Metadata
Title
Role of plasma neuropeptide Y in acute myocardial infarction: a case-control study
Authors
Yan-li Zheng
Hui-li Lin
Yue-ting Li
Mei-mei Li
Jing-ru Du
Wan-da Wang
Yao-guo Wang
Yin-lian Cai
Publication date
01-12-2024
Publisher
BioMed Central
Published in
BMC Cardiovascular Disorders / Issue 1/2024
Electronic ISSN: 1471-2261
DOI
https://doi.org/10.1186/s12872-024-04373-1

Keynote webinar | Spotlight on menopause

Menopause can have a significant impact on the body, with effects ranging beyond the endocrine and reproductive systems. Learn about the broader systemic effects of menopause, so you can help patients in your clinics through the transition.   

Prof. Martha Hickey
Dr. Claudia Barth
Dr. Samar El Khoudary
Developed by: Springer Medicine
Watch now

A quick guide to ECGs

Improve your ECG interpretation skills with this comprehensive, rapid, interactive course. Expert advice provides detailed feedback as you work through 50 ECGs covering the most common cardiac presentations to ensure your practice stays up to date. 

PD Dr. Carsten W. Israel
Developed by: Springer Medizin
Start the cases

Keynote webinar | Spotlight on medication adherence

  • Webinar | 27-06-2024 | 18:00 (CEST)

Medication non-adherence is a major barrier to effective healthcare delivery; half of all patients do not follow their doctor’s recommendations or treatment plan.

Our experts explain the fundamentals with a practical discussion of how to manage non-adherence in two common scenarios: hypertension and asthma control.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Watch now